New drug XTX501 takes aim at Hard-to-Treat cancers

NCT ID NCT07688577

Not yet recruiting Disease control Sponsor: Xilio Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests a new drug called XTX501 in people with metastatic non-small cell lung cancer (NSCLC) or other advanced solid tumors. The goal is to see if the drug is safe and can shrink tumors. Participants receive XTX501 alone, and researchers monitor side effects and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XTX501
What this could lead to: If successful, XTX501 could offer a new treatment option for people with advanced lung cancer or other solid tumors that have not responded to standard therapies.
What could go wrong: This is an early, first-in-human trial, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.